PPI-DAC

PPI-DAC is an early-stage biotechnology company focused on the discovery and development of small molecule therapeutics that target challenging protein-protein interactions (PPIs). The company utilizes a proprietary drug discovery platform that combines advanced computational modeling with specialized screening assays to identify novel binding sites on protein surfaces. By targeting these interactions, PPI-DAC aims to address high-value disease targets in oncology and inflammatory diseases that have historically been considered undruggable. The company's approach focuses on stabilizing or disrupting specific protein complexes to modulate disease pathways with high precision.